Altimmune, Inc.
For the period ended Jul 28, 2026. Filed Jul 28, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jul 28, 2026 · Filed Jul 28, 2026
ALT$2.08+5.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Efficacy Data
Efficacy Data
| Endpoint | Placebo | Pemvidutide | Treatment Effect | P-value |
|---|---|---|---|---|
| Change from baseline in HDD/Week at Week 24 (Primary Endpoint) | -2.75 (LS mean) | -4.20 (LS mean) | -1.45 (LS mean difference) | 0.0014 |
| 2-level Reduction in WHO-RDL | 34.8% (16/46) | 64.4% (29/45) | Odds Ratio 3.31 | 0.0049 |
| Zero HDD in Week 21 through Week 24 | 17.4% (8/46) | 42.2% (19/45) | Odds Ratio 3.84 | 0.0066 |
| Change from baseline in Percent of Days with Abstinence | 20.5% (LS mean) | 38.9% (LS mean) | 18.4% (LS mean difference) | 0.0075 |
| Change from baseline in Serum PEth at Week 24 | 22.0 (LS mean) | -153.4 (LS mean) | -175.3 (LS mean difference) | <0.0001 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.